Treatment group | Â | Days post-treatmenta
|
---|
 | Day 0 | Day 28–30 | Day 54–60 | Day 82–86 |
---|
Fluralanerb
| # Dogs | 34 | 34 | 33 | 33 |
Mean Scored
| 12.8 | 5.4 | 3.7 | 1.8 |
STDEV | 8.22 | 4.13 | 3.80 | 1.64 |
Range | (0–31) | (0–21) | (0–21) | (0–7) |
Reductione
| Â | 58.1Â % | 71.0Â % | 85.5Â % |
Afoxolanerc
| # Dogs | 27 | 27 | 26 | 23 |
Mean Scored
| 10.7 | 4.9 | 2.7 | 2.0 |
STDEV | 7.15 | 3.35 | 2.76 | 2.30 |
Range | (1–30) | (0–12) | (0–13) | (0–8) |
Reduction | Â | 54.0Â % | 74.5Â % | 81.3Â % |
-
aIn both groups dogs were treated on day 0. In the afoxolaner group dogs were also treated once between days 28–30 and once between days 54–60
-
bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
-
cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
-
dArithmetic mean Flea Allergy Dermatitis lesion score (Wilkerson et al. Vet Immunol Immunopathol 99(3–4):179–192, 2004)
-
e{(Day 0 arithmetic mean score—day x arithmetic mean score)/day 0 arithmetic mean score)} x 100